Skip to main content
. 2021 Sep 8;13(17):21134–21141. doi: 10.18632/aging.203377

Figure 3.

Figure 3

FTO represses the expression of Runx2 through its m6A demethylase activity. (A) The methylated RNA (m6A) level of Runx2, Sp7, Alp and Bglap in normal and FTO over-expressed BMSCs. *P<0.05. (B) The mRNA level of Runx2 in Wild-type or demethylase mutated FTO (R96Q) over-expressed BMSCs. *P<0.05. (C) The protein level of Runx2 in wild-type or demethylase mutated FTO (R96Q) over-expressed BMSCs. *P<0.05. (D) The methylated RNA (m6A) level of Runx2 in FTO down-regulated, wild-type or demethylase mutated FTO (R96Q) over-expressed BMSCs. *P<0.05. (E) Correlation between the mRNA level of FTO and Runx2 in the 20 cases of OP patients (R2=0.3735, P<0.01, Pearson’s correlation test). (F) Half-life of Runx2 mRNA in FTO down-regulated, wild-type or demethylase mutated FTO (R96Q) over-expressed BMSCs after transcription inhibition (TI). All values were normalized to 18S rRNA.